Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Oct 28, 2023
Date Accepted: Jan 10, 2024

The final, peer-reviewed published version of this preprint can be found here:

The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes in Patients With Diabetes Mellitus: Systematic Review and Meta-Analysis

Zhao L, Gao F, Zheng C, Sun X

The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes in Patients With Diabetes Mellitus: Systematic Review and Meta-Analysis

JMIR Public Health Surveill 2024;10:e53948

DOI: 10.2196/53948

PMID: 38564244

PMCID: 11022131

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis

  • Li Zhao; 
  • Feng Gao; 
  • Chunlan Zheng; 
  • Xuezhi Sun

ABSTRACT

Background:

Diabetes Mellitus (DM) increases the risk of developing tuberculosis (TB) and optimal glycemic control has been shown to reduce the risk of complications and improve the TB treatment outcomes in patients with DM.

Objective:

This study aims to investigate the role of glycemic control in improving TB treatment outcomes among patients with DM.

Methods:

MEDLINE, Embase, and Cochrane Central databases were searched for RCTs assessing the impact of oral glycemic control in TB patients who had DM. Outcomes of interest were radiological findings, treatment success, sputum positivity, and mortality. Evaluations were reported as risk ratios with 95% confidence intervals using weighted random-effects models.

Results:

The analysis included 6,919 patients from 7 observational studies. Meta-analysis showed statistically significant difference between patients with optimal glycemic control (OGC) and those with poor glycemic control (PGC) in improving treatment outcome[RR 1.13, 95%CI (1.02,1.25), P=0.02, I²=65%] , reducing sputum positivity [RR 0.23, 95%CI (0.09,0.61), P=0.003, I²=66%] and lesser cavitary lesions [RR 0.59, 95%CI (0.51, 0.68), P<0.00001, I²=0%] on radiological findings. There was no significant difference between the two groups in terms of mortality(RR 0.57, 95%CI (0.22,1.49), P=0.25, I²=0%], multilobar involvement (RR 0.57, 95%CI (0.22,1.49), P=0.25, I²=0%] on radiology, upper lobe [RR 0.94, 95% CI (0.76,1.17), P=0.58, I²=0%] and lower lobe [RR 1.05, 95% CI (0.48,2.30), P=0.91, I²=75%] involvement on radiology.

Conclusions:

we concluded that optimal glycemic control is crucial for reducing susceptibility, minimizing complications, and improving treatment outcomes in TB patients with DM. Emphasizing effective health management and healthcare strategies is essential in achieving this control. Integrating comprehensive care in TB patients with DM will enhance patient outcomes and alleviate the burden of disease in this population.


 Citation

Please cite as:

Zhao L, Gao F, Zheng C, Sun X

The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes in Patients With Diabetes Mellitus: Systematic Review and Meta-Analysis

JMIR Public Health Surveill 2024;10:e53948

DOI: 10.2196/53948

PMID: 38564244

PMCID: 11022131

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.